Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market For Sanofi And Regeneron’s Zaltrap Could Be Limited

This article was originally published in The Pink Sheet Daily

Executive Summary

Zaltrap gains FDA approval in metastatic colorectal cancer but must compete against several strongly entrenched treatments – Avastin, Vectibix and Erbitux.

You may also be interested in...



Market Snapshot: Zaltrap Changes Cost-Benefit Expectations For New Colon Cancer Drugs

Lilly’s Cyramza, Boehringer Ingelheim’s Vargatef and Taiho’s TAS-102 will join an increasingly crowded and price sensitive market in metastatic colorectal cancer in the coming years.

Sanofi Oncology’s Transformation Rests On Fedratinib, At Least In The Near-Term

The JAK2 inhibitor for myelofibrosis is the company’s most advanced oncology candidate and will be an anchor for Sanofi as it looks to build a portfolio of next-generation cancer drugs after the late-stage failure of the PARP inhibitor iniparib.

Side Effects Will Pressure Price Of Sanofi’s Zaltrap In Germany

Germany’s IQWiG could not fault Sanofi’s Zaltrap on clinical effectiveness in colorectal cancer, but its identification of serious adverse incidents is likely to depress the drug’s price there.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel